<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="107542">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01858363</url>
  </required_header>
  <id_info>
    <org_study_id>TP 1360</org_study_id>
    <nct_id>NCT01858363</nct_id>
  </id_info>
  <brief_title>CVI Drug Coated Balloon European Randomized Clinical Trial</brief_title>
  <official_title>Prospective, Randomized, Multi-center, Single-blinded Study for the Treatment of Subjects Presenting With De Novo Occluded/Stenotic or Re-occluded/Restenotic Lesions of the Superficial Femoral or Popliteal Arteries Using Paclitaxel or Bare Percutaneous Transluminal Angioplasty Balloon Catheter</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Covidien</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Covidien</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Austria: Austrian Medicines and Medical Devices Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, multi-center, single-blind study to demonstrate the
      safety and effectiveness of the CVI Paclitaxel-coated percutaneous transluminal angioplasty
      (PTA) balloon versus bare PTA balloon for the treatment of patients with de novo
      occluded/stenotic or reoccluded/restenotic lesions of the superficial femoral (SFA) and
      popliteal arteries.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Primary Efficacy Endpoint</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Primary Patency at 12 months post-procedure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Safety Endpoint</measure>
    <time_frame>30-Days and 12-Months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Freedom from device and procedure related target limb major amputation or death through 30-days post-procedure and clinically-driven target lesion revascularization at 12-month</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <condition>Claudication</condition>
  <arm_group>
    <arm_group_label>Paclitaxel-coated balloon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with de novo occluded/stenotic or re-occluded/restenotic lesions will be randomly assigned to treatment with a Paclitaxel-coated balloon or bare balloon.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bare balloon</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects with de novo occluded/stenotic or re-occluded/restenotic lesions will be randomly assigned to treatment with a Paclitaxel-coated balloon or bare balloon.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CVI Paclitaxel-coated Percutaneous Transluminal Angioplasty Balloon Catheter</intervention_name>
    <arm_group_label>Paclitaxel-coated balloon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bare Percutaneous Transluminal Angioplasty Balloon Catheter</intervention_name>
    <arm_group_label>Bare balloon</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic leg ischemia requiring treatment of the superficial femoral or popliteal
             arteries

          -  Rutherford clinical category 2, 3 or 4

          -  Male or non-pregnant female at least 18 years

        Exclusion Criteria:

          -  Co-existing clinically significant aneurismal disease of the abdominal aorta, iliac
             or popliteal arteries

          -  Significant gastrointestinal bleeding or any coagulopathy that would contraindicate
             the use of anti-platelet therapy

          -  Known intolerance of study medications, paclitaxel or contrast agent

          -  Active participation in another investigational device or drug study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henrik Schroeder, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Diagnostic Radiology &amp; Minimally Invasive Therapy, The Jewish Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AmaÃ«lle Vuillaume</last_name>
    <email>amaelle.vuillaume@covidien.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Center for Diagnostic Radiology and Minimally Invasive Therapy</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Henrik Schroeder, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 12, 2014</lastchanged_date>
  <firstreceived_date>May 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peripheral arterial disease</keyword>
  <keyword>claudication</keyword>
  <keyword>drug-coated balloon</keyword>
  <keyword>drug-eluting balloon</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
